Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
- Written by PR Newswire
![]() |
MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68Ga) gozetotide).
U.S. Launch Update:...